Rhodes Pharmaceuticals LP Sustainability Profile
Rhodes Pharmaceuticals LP, a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2006, the company has established itself as a leader in the development and manufacturing of generic and specialty pharmaceuticals, focusing on pain management and other therapeutic areas. With a commitment to quality and innovation, Rhodes Pharmaceuticals offers a range of unique products, including extended-release formulations that enhance patient compliance and treatment efficacy. The company has achieved significant milestones, including the successful launch of several key products that have strengthened its market position. Recognised for its dedication to advancing healthcare solutions, Rhodes Pharmaceuticals continues to expand its operational footprint across major regions in the US, solidifying its reputation as a trusted partner in the pharmaceutical landscape.
DitchCarbon Score
How does Rhodes Pharmaceuticals LP's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Rhodes Pharmaceuticals LP's score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Rhodes Pharmaceuticals LP's reported carbon emissions
Rhodes Pharmaceuticals LP, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is classified as a current subsidiary and does not inherit emissions data from a parent organisation. Consequently, there are no documented reduction targets or climate pledges available for review. As a subsidiary, Rhodes Pharmaceuticals LP may align its climate commitments with broader industry standards and practices, but specific initiatives or targets have not been disclosed. The lack of emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction, often setting science-based targets to mitigate their environmental impact. However, without specific commitments or data from Rhodes Pharmaceuticals LP, it is challenging to assess their current standing in relation to industry peers.
How Carbon Intensive is Rhodes Pharmaceuticals LP's Industry?
How Carbon Intensive is Rhodes Pharmaceuticals LP's Location?
Rhodes Pharmaceuticals LP's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Rhodes Pharmaceuticals LP has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
